Kohjin Bio Co.,Ltd. (JP:177A)

:177A

177A

Kohjin Bio Co.,Ltd.

RESEARCH TOOLSreports

Want to see JP:177A full AI Analyst Report?

Kohjin Bio Co.,Ltd. (177A) Price & Analysis

0 Followers

177A Stock Chart & Stats

¥1525.00

-¥17.00(-1.03%)

At close: Jan 08 4:00 PM EST

¥1525.00

-¥17.00(-1.03%)

Day’s Range― - ―

52-Week Range¥961.00 - ¥2,020.00

Previous CloseN/A

Volume7.50K

Average Volume (3M)3.64K

Market Cap

¥5.23B

Enterprise Value¥4.85B

Total Cash (Recent Filing)¥3.10B

Total Debt (Recent Filing)¥1.99B

Price to Earnings (P/E)22.1

Beta0.79

Next Earnings

Aug 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.62%

Share Statistics

EPS (TTM)139.68

Shares Outstanding5,111,600

10 Day Avg. Volume4,170

30 Day Avg. Volume3,643

Financial Highlights & Ratios

PEG Ratio-0.36

Price to Book (P/B)1.04

Price to Sales (P/S)1.25

P/FCF Ratio-22.03

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)¥5.58B

Bulls Say, Bears Say

Bulls Say

Improving LeverageDebt-to-equity falling to ~0.37 and a materially stronger equity base provide durable financial flexibility. Lower leverage reduces interest burden and bankruptcy risk, enabling the company to fund operations or opportunistic investment over the next several quarters without immediate refinancing pressure.

Historical Margin StrengthThe company has demonstrated the ability to deliver high operating and net margins historically, indicating structural pricing power or cost advantages. That track record suggests the business model can support margin recovery if revenue stabilizes, a durable positive over a multi-month horizon.

Positive Operating Cash FlowConsistent positive operating cash flow signals the core business generates cash from operations, supporting working capital and R&D without constant external financing. While FCF is volatile, ongoing OCF is a lasting indicator of underlying cash generation capacity.

Bears Say

Revenue DeclineA near-5% revenue decline reflects weakening demand or loss of sales momentum. Persistent revenue contraction erodes scale, limits margin recovery potential, and undermines the durability of prior profitability, making mid-term earnings and cash-flow stabilization more challenging.

Compressed ProfitabilityA sharp drop in net margin signals structural pressure on pricing, costs, or product mix. Lower profitability reduces retained earnings and ROE, limiting reinvestment and heightening sensitivity to future revenue shocks, which can persistently weaken balance-sheet efficiency.

Negative Free Cash FlowA negative FCF outflow undermines the firm's ability to self-fund capex, R&D, or dividends without tapping external capital. If FCF volatility persists, it increases refinancing and funding risk and constrains strategic initiatives despite lower leverage.

177A FAQ

What was Kohjin Bio Co.,Ltd.’s price range in the past 12 months?

Kohjin Bio Co.,Ltd. lowest stock price was ¥961.00 and its highest was ¥2020.00 in the past 12 months.

What is Kohjin Bio Co.,Ltd.’s market cap?

Kohjin Bio Co.,Ltd.’s market cap is ¥5.23B.

When is Kohjin Bio Co.,Ltd.’s upcoming earnings report date?

Kohjin Bio Co.,Ltd.’s upcoming earnings report date is Aug 13, 2026 which is in 68 days.

How were Kohjin Bio Co.,Ltd.’s earnings last quarter?

Kohjin Bio Co.,Ltd. released its earnings results on May 15, 2026. The company reported -¥5.6 earnings per share for the quarter, missing the consensus estimate of N/A by -¥5.6.

Is Kohjin Bio Co.,Ltd. overvalued?

According to Wall Street analysts Kohjin Bio Co.,Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Kohjin Bio Co.,Ltd. pay dividends?

Kohjin Bio Co.,Ltd. pays a Notavailable dividend of ¥24 which represents an annual dividend yield of 1.62%. See more information on Kohjin Bio Co.,Ltd. dividends here

What is Kohjin Bio Co.,Ltd.’s EPS estimate?

Kohjin Bio Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kohjin Bio Co.,Ltd. have?

Kohjin Bio Co.,Ltd. has 5,111,600 shares outstanding.

What happened to Kohjin Bio Co.,Ltd.’s price movement after its last earnings report?

Kohjin Bio Co.,Ltd. reported an EPS of -¥5.6 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -23.838%.

Which hedge fund is a major shareholder of Kohjin Bio Co.,Ltd.?

Currently, no hedge funds are holding shares in JP:177A

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Kohjin Bio Co.,Ltd.

Kohjin Bio Co., Ltd. manufactures and sells animal blood, sera, tissue culture media, agar media for microorganism tests, in-vitro diagnostic agents, and cosmetics. The company offers tissue culture mediums for virus and recombinant protein production, hybridoma, human lymphocyte culture, and insect cell lines; gas permeable cell culture bags and other materials; cryopreservation agent of cells; medium supplements; normal human cells; normal human cell mediums; ES cell mediums; in-vitro fertilization and early embryo culture kits; and other culture and related products, such as supplements, cell separation solutions, physiological salt solutions, and research reagents. The company also offers clinical microbiology culture mediums for gram positive cocci, gram negative bacteria, and susceptibility testing; general differential, anaerobic growth, and fungal mediums; tube mediums for confirmation and expansion; microbiology culture mediums for food, such as mediums for sterilization test, E. coli and coliform bacteria, staphylococcus spp., bacillus cereus, and vibrio parahaemolyticus; culture mediums for determining total viable cell count; and campylobacter and fungal mediums. In addition, the company offers normal human blood, serum, and plasma; pathological human serum; preserved animal blood; defibrinated and hemolyzed animal blood; animal serum and plasma; and other custom-designed products, such as eagle medium. Further, the company engages in the production and sale of laboratory animal, sale of medical equipment, trust of animal immunization and antibody preparation, and import and export of products and raw materials. The company was formerly known as Kohjin Co.,Ltd and changed its name to Kohjin Bio Co., Ltd. in 1989. The company was incorporated in 1981 and is based in Sakado, Japan.